Vascular Biogenics vbl.co.il


Public list: Pharma Startups (4732) Cancer Therapeutics (1137)

Vascular Biogenics (VBL) is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapies are limited in their ability to adequately treat these serious and oftentimes life-threatening diseases. VBL was founded to create new treatment options that address these unmet medical needs. VBL's clinical pipeline is based on two distinct, prop...Show all

Vascular Biogenics (VBL) is an innovative and diversified, clinical stage biotechnology company committed to the discovery, development and commercialization of novel treatments for cancer and immune-inflammatory diseases. Currently available therapi...Show all

Company (IPO / Went public)

Phone: 972-3-6346450

Fax:

6 Jonathan Netanyahu St.

Or Yehuda, 60376
Israel

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Vascular Biogenics $64.8M Jul 31, 2014
See all 16 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Vascular Biogenics Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 6 investors

Competitors

Company Status Description Investors
See all 16 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
High-purity phospholipids Feb 13, 2017 May 15, 2018 Patent
Oxidized lipids Nov 25, 2015 Sep 26, 2017 Patent
Methods of inducing responsiveness to anti-angiogenic agent Feb 04, 2014 Jun 20, 2017 Patent
High-purity phospholipids Feb 25, 2015 Feb 14, 2017 Patent
Methods for use of a specific anti-angiogenic adenoviral agent Jan 05, 2011 Feb 14, 2017 Patent
See all 50 patents